Difference between revisions of "User:Cecilia Cisar/Notebook/Mod 3 Research Proposal"

From OpenWetWare
Jump to: navigation, search
(Potential Problems)
 
(21 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{|{{table}} width="800"
 
{|{{table}} width="800"
 
|colspan="2"|
 
|colspan="2"|
==Project Description/Abstract==
+
==Project Description==
 
* To design bacteria that use specific miRNA signatures to target cancer cells.
 
* To design bacteria that use specific miRNA signatures to target cancer cells.
 +
* [[20.109%28S14%29:Module_3_oral_presentations | Overview for this assignment and FAQ]]
  
 
==Overview==
 
==Overview==
* During certain stages of growth, cancer cells exhibit unique miRNA signatures.<cite>Calin, George A., and Carlo M. Croce. "MicroRNA signatures in human cancers." Nature Reviews Cancer 6.11 (2006): 857-866.</cite>
+
* MiRNAs are believed to be important in oncogenesis, as different groups of miRNAs act as either tumor suppressors or oncogenes. For example, miR-145, miR-133a and miR-133b have been found to be tumor-suppressive miRNAs that directly regulate the oncogene FSCN1. [5]  Changes in miRNA expression have been detected in many types of human cancers, in a way that seems to be linked to genomic amplifications, mutations, and deletions. "MiRNA expression fingerprints correlate with clinical and biological characteristics of tumours, including tissue type, differentiation, aggression and response to therapy." [1]
  
* Some organisms use miRNA to target and inhibit sections of bacterial DNA.<cite>Ma, Feng, et al. "The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-[gamma]."Nature immunology 12.9 (2011): 861-869.</cite>
+
* Some bacteria use miRNA to target and post-transcriptionally repress proteins that are involved in innate immune response, [2] and other bacteria release effectors that inhibit miRNA immune response. [3] (Conversely, some miRNA-regulated immune response pathways are activated by bacteria. [4])
 +
 
 +
* Bacteria could be designed to treat various kinds of tumors based on their miRNA expression fingerprint through up/down regulation of oncogene miRNA expression.
 +
 
 +
==Potential Problems==
 +
*Immune response
 +
**Cancer patients may already be immunocompromised through other treatments, so this may not be as big of an issue as it would initially seem, but this leads to...
 +
*Pathogenicity
 +
**If my 20.020 project taught me anything, it's that people are squeamish about introducing bacteria into things even if there isn't anything to point towards it being problematic.
 +
**Would saying that there ''should'' be nothing wrong with the chassis and that it'll have to go through clinical testing be enough?
 +
*Targeting of cancer cells
 +
**Bacteria do not specifically target things based on miRNA signatures
 +
**Could we rely on bacteria to stay localized, depending on treatment method?
 +
**Would regulation of oncogenes in non-target area be an issue? I want to think it would just make cancer-causing mutations even ''less'' likely in affected areas, even if they were not cancerous in the first place...
 +
*Targeting of miRNAs
 +
**This is going to be what we say the focus of the research will be, right?
 +
**Do we know enough to take a stab at this?  It may be worth reading that third paper closer to see if they specify any sort of mechanism...
  
 
==References==
 
==References==
<references />
+
# [http://www.gene-quantification.eu/nature-reviews-microrna-3.pdf Calin, George A., and Carlo M. Croce. "MicroRNA signatures in human cancers." Nature Reviews Cancer 6.11 (2006): 857-866.]
 
+
# [http://download.bioon.com.cn/view/upload/201110/19180817_1775.pdf Ma, Feng, et al. "The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ."Nature immunology 12.9 (2011): 861-869.]
 +
# [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570098/ Navarro, Lionel, et al. "Suppression of the microRNA pathway by bacterial effector proteins." Science 321.5891 (2008): 964-967.]
 +
# [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1567904/?report=reader Taganov, Konstantin D., et al. "NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses." Proceedings of the National Academy of Sciences 103.33 (2006): 12481-12486.]
 +
# [http://onlinelibrary.wiley.com/doi/10.1002/ijc.25284/full Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., Chiyomaru, T., Enokida, H., Nakagawa, M. and Matsubara, H. (2010), miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer, 127: 2804–2814.]
 
|-
 
|-
 
|colspan="2" style="background-color: #F2F2F2;"|
 
|colspan="2" style="background-color: #F2F2F2;"|
 
{{LnNotebookRecentChanges2}}
 
{{LnNotebookRecentChanges2}}
 
|}
 
|}

Latest revision as of 09:09, 7 May 2014

Project Description

Overview

  • MiRNAs are believed to be important in oncogenesis, as different groups of miRNAs act as either tumor suppressors or oncogenes. For example, miR-145, miR-133a and miR-133b have been found to be tumor-suppressive miRNAs that directly regulate the oncogene FSCN1. [5] Changes in miRNA expression have been detected in many types of human cancers, in a way that seems to be linked to genomic amplifications, mutations, and deletions. "MiRNA expression fingerprints correlate with clinical and biological characteristics of tumours, including tissue type, differentiation, aggression and response to therapy." [1]
  • Some bacteria use miRNA to target and post-transcriptionally repress proteins that are involved in innate immune response, [2] and other bacteria release effectors that inhibit miRNA immune response. [3] (Conversely, some miRNA-regulated immune response pathways are activated by bacteria. [4])
  • Bacteria could be designed to treat various kinds of tumors based on their miRNA expression fingerprint through up/down regulation of oncogene miRNA expression.

Potential Problems

  • Immune response
    • Cancer patients may already be immunocompromised through other treatments, so this may not be as big of an issue as it would initially seem, but this leads to...
  • Pathogenicity
    • If my 20.020 project taught me anything, it's that people are squeamish about introducing bacteria into things even if there isn't anything to point towards it being problematic.
    • Would saying that there should be nothing wrong with the chassis and that it'll have to go through clinical testing be enough?
  • Targeting of cancer cells
    • Bacteria do not specifically target things based on miRNA signatures
    • Could we rely on bacteria to stay localized, depending on treatment method?
    • Would regulation of oncogenes in non-target area be an issue? I want to think it would just make cancer-causing mutations even less likely in affected areas, even if they were not cancerous in the first place...
  • Targeting of miRNAs
    • This is going to be what we say the focus of the research will be, right?
    • Do we know enough to take a stab at this? It may be worth reading that third paper closer to see if they specify any sort of mechanism...

References

  1. Calin, George A., and Carlo M. Croce. "MicroRNA signatures in human cancers." Nature Reviews Cancer 6.11 (2006): 857-866.
  2. Ma, Feng, et al. "The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ."Nature immunology 12.9 (2011): 861-869.
  3. Navarro, Lionel, et al. "Suppression of the microRNA pathway by bacterial effector proteins." Science 321.5891 (2008): 964-967.
  4. Taganov, Konstantin D., et al. "NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses." Proceedings of the National Academy of Sciences 103.33 (2006): 12481-12486.
  5. Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., Chiyomaru, T., Enokida, H., Nakagawa, M. and Matsubara, H. (2010), miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer, 127: 2804–2814.
Recent changes

25 September 2017

     21:19 

BME100 f2017:Group12 W0800 L3‎‎ (12 changes | history) . . (+3,361). . [Priscilla Y. Han‎ (12×)]

     

21:19

(cur | prev) . . (+25). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

21:15

(cur | prev) . . (+70). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

21:11

(cur | prev) . . (-3). . Priscilla Y. Han (talk | contribs) (Experimental Design of Device)

     

21:10

(cur | prev) . . (-12). . Priscilla Y. Han (talk | contribs) (Experimental Design of Device)

     

21:10

(cur | prev) . . (+15). . Priscilla Y. Han (talk | contribs) (Experimental Design of Device)

     

21:09

(cur | prev) . . (+3,181). . Priscilla Y. Han (talk | contribs) (Experimental Design of Device)

     

21:05

(cur | prev) . . (+5). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

21:03

(cur | prev) . . (+25). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

21:01

(cur | prev) . . (+2). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

20:58

(cur | prev) . . (+29). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

20:57

(cur | prev) . . (-3). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     

20:55

(cur | prev) . . (+27). . Priscilla Y. Han (talk | contribs) (Descriptive Stats and Graph)

     21:19 

(Upload log). .

[Ana C. Carr‎ (4×); Priscilla Y. Han‎ (7×)]

     

21:19

. . Priscilla Y. Han (talk | contribs) uploaded File:Pulsingbargraph12.png

     

21:18

. . Priscilla Y. Han (talk | contribs) uploaded File:Mypear sonheart12.png

     

21:18

. . Priscilla Y. Han (talk | contribs) uploaded File:Heartratespree12.png

     

21:04

. . Priscilla Y. Han (talk | contribs) uploaded File:Scrnshotspree12.png

     

20:59

. . Priscilla Y. Han (talk | contribs) uploaded File:2columnbarsspree.png

     

20:56

. . Priscilla Y. Han (talk | contribs) uploaded a new version of File:Mypear sonr.png

     

20:56

. . Priscilla Y. Han (talk | contribs) uploaded File:Mypear sonr.png

     

18:36

. . Ana C. Carr (talk | contribs) uploaded a new version of File:IMG 5562.jpg(In action)

     

18:36

. . Ana C. Carr (talk | contribs) uploaded a new version of File:IMG 5562.jpg(In action)

     

18:36

. . Ana C. Carr (talk | contribs) uploaded a new version of File:IMG 5562.jpg(In action)

     

18:36

. . Ana C. Carr (talk | contribs) uploaded a new version of File:IMG 5562.jpg(In action)

     20:33 

BME100 f2017:Group8 W1030 L3‎‎ (9 changes | history) . . (+501). . [Jennifer L. Brodsky‎ (9×)]

     

20:33

(cur | prev) . . (+5). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:32

(cur | prev) . . (+112). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:29

(cur | prev) . . (0). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:28

(cur | prev) . . (+13). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:28

(cur | prev) . . (-1). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:26

(cur | prev) . . (+1). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:26

(cur | prev) . . (+177). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:25

(cur | prev) . . (+7). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

     

20:24

(cur | prev) . . (+187). . Jennifer L. Brodsky (talk | contribs) (Experimental Design of Own Device)

N    20:17  BME100 f2017:Group10 W0800 L3‎ (diff | hist) . . (+767). . Whitney Hirano (talk | contribs) (Created page with "5. The mean value of heart rate calculated from the pulse ox was 98.3673 beats/min with a standard deviation of 22.2273, while the mean value of heart rate calculated from the...")
     19:56  BME100 f2017:Group9 W0800 L3‎ (diff | hist) . . (+3). . Irene Zhang (talk | contribs) (LAB 3 WRITE-UP)

     19:52 

BME100 f2017:Projects1‎‎ (3 changes | history) . . (+19). . [Yar‎; Karmella Haynes‎ (2×)]

     

19:52

(cur | prev) . . (0). . Yar (talk | contribs) (small change to force cache purge)

     

19:37

(cur | prev) . . (+21). . Karmella Haynes (talk | contribs)

     

19:11

(cur | prev) . . (-2). . Karmella Haynes (talk | contribs) (Lab 1: “Needs Identification”)

     19:19  CONJ606:Schedule‎ (diff | hist) . . (+23). . Maureen E. Hoatlin (talk | contribs) (Week-by-Week Schedule Summary)

     19:06 

BME100 f2017‎‎ (2 changes | history) . . (+1). . [Karmella Haynes‎ (2×)]

     

19:06

(cur | prev) . . (-8). . Karmella Haynes (talk | contribs)

     

19:06

(cur | prev) . . (+9). . Karmella Haynes (talk | contribs)

     17:38  User:Oww Bot‎ (diff | hist) . . (-956). . Yar (talk | contribs) (it me)

     17:36 

(User rights log). .

[Yar‎ (2×)]

     

17:36

. . Yar (talk | contribs) changed group membership for Oww Bot from bot and administrator to bot ‎

     

17:33

. . Yar (talk | contribs) changed group membership for Yeem from administrator to (none) ‎

     17:35  User:Yar‎ (diff | hist) . . (+26). . Yar (talk | contribs) (my name)

     17:34 

(Move log). .

[Yar‎ (5×)]

     

17:34

. . Yar (talk | contribs) moved page User talk:Yardena Cohen to User talk:Yar(Automatically moved page while renaming the user "Yardena Cohen" to "Yar")

     

17:34

. . Yar (talk | contribs) moved page User:Yardena Cohen/Notebook/attempt/Entry Base to User:Yar/Notebook/attempt/Entry Base(Automatically moved page while renaming the user "Yardena Cohen" to "Yar")

     

17:34

. . Yar (talk | contribs) moved page User:Yardena Cohen/Notebook/attempt to User:Yar/Notebook/attempt(Automatically moved page while renaming the user "Yardena Cohen" to "Yar")

     

17:34

. . Yar (talk | contribs) moved page User:Yardena Cohen/Notebook to User:Yar/Notebook(Automatically moved page while renaming the user "Yardena Cohen" to "Yar")

     

17:34

. . Yar (talk | contribs) moved page User:Yardena Cohen to User:Yar(Automatically moved page while renaming the user "Yardena Cohen" to "Yar")

     17:34 (User rename log) . . Yar (talk | contribs) renamed user Yardena Cohen (108 edits) to Yar(shorter)